Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Grepafloxacin

A J Wagstaff1, J A Balfour

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Grepafloxacin, a novel fluoroquinolone antibiotic, shows enhanced activity against Gram-positive bacteria like Streptococcus pneumoniae. Clinical trials confirm its efficacy in treating respiratory and gonococcal infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis.

QJM : monthly journal of the Association of Physicians·2014
Same author

No lasting legacy: no change in reporting of women's sports in the British print media with the London 2012 Olympics and Paralympics.

Journal of public health (Oxford, England)·2014
Same author

Levetiracetam.

CNS drugs·2013
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Recombinant Mammalian Cell-Derived Somatropin: A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Wasting Associated with HIV Infection.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Fluoroquinolones are broad-spectrum antibiotics with good tissue penetration.
  • There is a need for agents with improved activity against Gram-positive pathogens, such as Streptococcus pneumoniae.

Purpose of the Study:

  • To evaluate the in vitro and in vivo properties of grepafloxacin.
  • To compare the efficacy of grepafloxacin with existing antibiotics in clinical trials.

Main Methods:

  • In vitro antimicrobial susceptibility testing against various bacterial strains.
  • Animal studies to assess safety, including potential for convulsions and phototoxicity.
  • Comparative clinical trials for community-acquired pneumonia, respiratory tract infections, and gonorrhea.

Related Experiment Videos

Main Results:

  • Grepafloxacin demonstrated potent activity against Streptococcus pneumoniae, including penicillin-resistant strains, showing 4-fold higher potency than ciprofloxacin.
  • In vitro activity against Enterobacteriaceae was comparable to ciprofloxacin.
  • Animal studies showed no convulsions at high doses with NSAIDs and low phototoxicity potential.
  • Clinical trials indicated grepafloxacin was as effective as amoxicillin, ofloxacin, and cefixime for respective indications.

Conclusions:

  • Grepafloxacin is a promising once-daily fluoroquinolone with broad-spectrum activity and improved Gram-positive efficacy.
  • It is effective and well-tolerated for community-acquired pneumonia, respiratory tract infections, and gonorrhea.
  • Its favorable safety profile and potent activity make it a valuable therapeutic option.